Inspire Medical Systems has officially launched EuroStim, a first-of-its-kind European registry for hypoglossal nerve stimulation in sleep apnea treatment. The registry will track up to 1,000 patients across 50 centers, beginning with the first enrollment at TU Munich in Germany.
Designed to gather long-term data over a 10-year span, EuroStim will evaluate device battery life and real-world outcomes of Inspire therapy, aiming to strengthen clinical evidence for the neuromodulation solution.
The launch aligns with Inspire’s recent momentum, including its next-gen Inspire V system rollout, improved financial performance, and a $75 million share buyback initiative.
However, the company is also under legal scrutiny, following a civil investigation demand from the DOJ regarding potential violations of the Anti-Kickback Statute.
Follow MEDWIRE.AI for updates on sleep apnea innovation and regulatory developments.
